What is the recommended dosing regimen for citalopram, including initial dose, maintenance dose, maximum dose, and adjustments for patients aged 60 years or older, hepatic impairment, and concomitant use of strong CYP2C19 inhibitors or other serotonergic agents?

Citalopram Dosing

Start citalopram at 20 mg once daily and increase to a maximum of 40 mg/day after at least one week if needed, but reduce the maximum dose to 20 mg/day in patients over 60 years old, those with hepatic impairment, or CYP2C19 poor metabolizers taking strong CYP2C19 inhibitors like cimetidine or omeprazole due to QT prolongation risk. 1

Standard Dosing Regimen

Initial Dose

• 20 mg once daily (morning or evening, with or without food) 1
• Can start with lower "test" doses (10 mg) in patients prone to anxiety or agitation as initial adverse effects 2

Maintenance Dose

• Continue 20 mg daily if effective and well-tolerated
• May increase to 40 mg/day maximum after minimum 1 week interval 1
• Doses above 40 mg/day are contraindicated due to dose-dependent QTc prolongation risk 1

Titration Strategy

• Increase in smallest available increments at 1-2 week intervals for shorter half-life SSRIs like citalopram 2
• The 60 mg/day dose showed no additional benefit over 40 mg/day in clinical trials 1

Special Population Dose Adjustments

Age ≥60 Years

Maximum 20 mg/day 1

Rationale: Elderly patients show 30-50% increased AUC and half-life compared to younger adults 1. Steady-state levels can be 2-4 times higher than expected, with half-lives extending to 1.5-3.75 days versus 1.5 days in younger patients 3. The FDA and EMA restricted maximum doses following QT prolongation studies 4.

Hepatic Impairment

Maximum 20 mg/day 1

Rationale: Oral clearance reduced by 37% with doubled half-life (approximately 83 hours vs 37 hours) in hepatic cirrhosis 1, 5. Systemic clearance decreases significantly (0.21 vs 0.33 L/h/kg in healthy subjects) 5.

Renal Impairment

• Mild to moderate: No dose adjustment needed 1
• Severe (CrCl <20 mL/min): Use with caution; no specific data available 1
• Renal clearance accounts for <20% of total elimination 1, and oral clearance reduced only 17% in mild-moderate impairment 5

CYP2C19 Poor Metabolizers

Maximum 20 mg/day 1

Rationale: CYP2C19 poor metabolizers (PM/PM genotype with *2 or *3 alleles) show 95% increased exposure compared to extensive metabolizers 6. CYP2C19 is the primary enzyme for citalopram N-demethylation 1, 7. Poor metabolizers demonstrate 68% higher Cmax and 107% higher AUC at steady state 1.

Strong CYP2C19 Inhibitors

Maximum 20 mg/day when co-administered with:

• Cimetidine
• Omeprazole or esomeprazole
• Other potent CYP2C19 inhibitors 1

Rationale: These inhibitors significantly increase citalopram exposure, particularly in older adults where DDI risk is amplified 8. The effect varies by CYP2C19 phenotype, with greatest impact in extensive metabolizers converted to functional poor metabolizers 8.

Critical Safety Considerations

QT Prolongation Risk - Absolute Contraindications

Do NOT use citalopram in patients with: 1

• Congenital long QT syndrome
• Bradycardia
• Hypokalemia or hypomagnesemia (until corrected)
• Recent acute myocardial infarction
• Uncompensated heart failure
• Concurrent use of other QTc-prolonging drugs (Class IA/III antiarrhythmics, typical/atypical antipsychotics, certain antibiotics)

Monitoring Requirements

• Baseline: Serum potassium and magnesium in at-risk patients 1
• ECG monitoring: Required if citalopram use deemed essential despite contraindications 1
• Discontinue if QTc >500 ms 1
• Evaluate patients with dizziness, palpitations, or syncope for cardiac arrhythmias 1

Serotonin Syndrome Risk

Exercise extreme caution when combining with other serotonergic agents 2, 1:

• MAOIs (contraindicated; allow 14-day washout) 1
• Other SSRIs/SNRIs
• Triptans, tramadol, fentanyl
• Tricyclic antidepressants
• Lithium, buspirone, St. John's Wort
• Amphetamines, dextromethorphan

When combining non-MAOI serotonergic drugs: Start second agent at low dose, increase slowly, monitor closely in first 24-48 hours after dose changes 2.

Discontinuation Protocol

Taper gradually rather than abrupt cessation 1

• Reduce dose over 10-14 days minimum 9
• If intolerable symptoms occur, resume previous dose then taper more slowly 1
• Citalopram has shorter half-life than fluoxetine, making discontinuation syndrome more likely 2

Common discontinuation symptoms: Dizziness, fatigue, myalgias, headaches, nausea, insomnia, sensory disturbances, anxiety, irritability 2

Clinical Pearls

• No gender-based adjustment needed despite some pharmacokinetic variability 1
• CYP2D6 poor metabolizers: No dose adjustment required 1
• Citalopram/escitalopram have least effect on CYP450 enzymes, resulting in lower drug interaction potential compared to other SSRIs 2
• Full therapeutic trial requires 4-8 weeks at therapeutic dose 9
• After 9 months, consider dose reduction to reassess need for continued treatment 9
• Well-tolerated overall; common side effects include nausea and sleep disturbances 9